Ocular manifestations of diabetes mellitus

Current Opinion in Ophthalmology

Volumn 10, Issue 6, 1999, Pages 483-489

  Stanga, P E ^a   Boyd, S R ^a   Hamilton, A M P ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RUBOXISTAURIN;

ARTICLE; CATARACT; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; HEALTH PROMOTION; HUMAN; NEUROOPHTHALMOLOGY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SCREENING; UVEITIS;

DIABETES COMPLICATIONS; DIABETES MELLITUS; EYE DISEASES; HUMANS; PATIENT EDUCATION; PROGNOSIS;

EID: 0032751671     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199912000-00018     Document Type: Article

References (117)

1. 1 Gruber W, Lander T, Leese B, et al.: Diabetes Health Economics Study Group: The Economics of Diabetes and Diabetes Care. Geneva: International Diabetes Federation and World Health Organization; 1997.
2. 2 Sanchez Thorin JC: The epidemiology of diabetes mellitus and diabetic retinopathy. Int Ophthalmol Clin 1998, 38:11-18.
3. 3 Recchia FM, Connolly B, Benson WE: Ocular manifestations of diabetes. Curr Opin Ophthalmol 1998, 9:64-68.
4. 4 Ducrey N; Ophthalmologic complications of diabetes except for diabetic retinopathy. J Fr Ophtalmol 1999, 22:400-407.
5. 5 Neely KA, Quillen DA, Schachat AP, Gardner TW, Blankenship GW: Diabetic retinopathy. Med Clin North Am 1998, 82:847-876.
6. 6 Dowse GK, Humphrey AR, Collins VR, et al.: Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol 1998, 147:448-457.
7. 7 National Society to Prevent Blindness: Vision problems in the U.S. Data Analysis, Definitions, Data Sources, Detailed Data Tables, Analysis, Interpretation. New York: National Society to Prevent Blindness; 1980.
8. 8 Hirvela H, Laatikainen L: Diabetic retinopathy in people aged 70 years or older. The Oulu Eye Study. Br J Ophthalmol 1997, 81:214-217.
9. 9 Sjolie AK, Stephenson J, Aldington S, et al.: Retinopathy and vision loss in insulin-dependent diabetes in Europe: The EURODIAB IDDM Complications Study. Ophthalmology 1997, 104:252-260.
10. 10 Taylor RH, Jones HS, Dodson PM, et al.: Diabetic eye disease: a natural history study. Eye 1997, 11:547-553.
11. 11 Berinstein DM, Stahn RM, Welty TK, et al.: The prevalence of diabetic retinopathy and associated risk factors among Sioux Indians. Diabetes Care 1997, 20:757-759.
12. 12 Gonzalez Villalpando ME, Klein R, Haffner SM, Stern MP: Moderate-to-severe diabetic retinopathy is more prevalent in Mexico City than in San Antonio, Texas. Diabetes Care 1997, 20:773-777.
13. 13 The Early Treatment Diabetic Retinopathy Study Group: Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification (Early Treatment Diabetic Retinopathy Study rep. no. 10). Ophthalmology 1991, 98:786-806.
14. 14 The Diabetes Control and Complications Trial (DCCT): Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995, 102:647-661.
15. 15 The Kroc Collaborative Study Group: Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA 1998, 260:37-41.
16. 16 Dahl Jorgensen K, Brinchmann Hansen O, Hanssen KF, et al.: Effect of near normoglysemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J Clin Res Ed 1986, 293:1195-1199.
17. 17 Cunha-Vaz J: Lowering the risk of visual impairment and blindness. Diabet Med 1998, 15(suppl 4):S47-S50.
18. 18 Dryakova M, Cerovska J, Vondrova H, Sosna T: Clinical development of unstable (brittle) diabetes mellitus, its therapy and prognosis. Vnitr Lek 1998, 44:355-360.
19. 19 Neely KA, Quillen DA, Shachat AP, et al.: Diabetic retinopathy. Med Clin North Am 1998, 82:847-876.
20. 20 Mitchell P, Smith W, Wang JJ, Attebo K: Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 1998, 105:406-411.
21. 21 Kohner EM, Aldington SJ, Stratton IM, et al.: United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998, 116:297-303. This paper shows that lowering both systolic and diastolic blood pressure in type II diabetes is important in reducing the progression of retinopathy.
22. 22 Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998, 105:998-1003.
23. 23 Ono Y, Aoki S, Ohnishi K, et al.: Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998, 41: 131-137.
24. 24 Tovi J, Ingemansson SO, Engfoldt P: Insulin treatment of elderly type 2 diabetic patients: effects on retinopathy. Diabetes Metab 1998, 24:442-447.
25. 25 Gerstein HC: Glucose: a continuous risk factor for cardiovascular disease. Diabet Med 1997, 14(suppl 3):S25-S31.
26. 26 Preventive-care knowledge and practices among persons with diabetes mellitus-North Carolina. Behavioural Risk Factor Surveillance System, 1994-1995. MMWR Morb Mortal Wkly Rep 1997,46:1023-1027.
27. 27 Lawler FH, Viviani N: Patient and physician perspectives regarding treatment of diabetes: compliance with practice guidelines. J Fam Pract 1997,44:369-373.
28. 28 Nicolucci A, Scorpiglione N, Belfiglio M, et al.: Patterns of care in an Italian population. The Italian Study Group for the Implementation of the St Vincent Declaration, Societa Italiana di Diabetologia, Associazione Medici Diabetologi. Diabet Med 1997, 14:158-166.
29. 29 Beckles GL, Engelgau MM, Venkat Narayan KM, et al.: Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 1998, 21:1432-1438.
30. 30 Cook CB, Penman A, Cobb AB, et al.: Outpatient diabetes management of Medicare beneficiaries in four Mississippi fee-for-service primary care clinics. J Miss State Med Assoc 1999, 40:8-13.
31. 31 Hermayer KL, Jenkins C, Gunter DN, et al.: Physician office-based diabetes care: comparison for guidelines for care. J S C Med Assoc 1998, 94:485-491.
32. 32 Wang F, Javitt JC: Eye care for elderly Americans with diabetes mellitus. Failure to meet current guidelines. Ophthalmology 1996, 103:1744-1750.
33. 33 Baker RS, Watkins NL, Wilson MR, et al.: Demographic and clinical characteristics of patients with diabetes presenting to an urban public hospital ophthalmology clinic. Ophthalmology 1998, 105:1373-1379.
34. 34 Rubin RJ, Dietrich KA, Hawk AD: Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 1998, 83:2635-2642.
35. 35 Lowe JM, Bowen K: Evaluation of a diabetes education program in Newcastle, NSW. Diabetes Res Clin Pract 1997, 38:91-99.
36. 36 Goodman GR, Zwarenstein MF, Robinson II, Levitt NS: Staff knowledge, attitudes and practices in public sector primary care of diabetes in Cape Town, S Afr Med J 1997, 87:305-309.
37. 37 Diabetes-specific preventive-care practices among adults in a managed-care-population-Colorado, Behavioural Risk Factor Surveillance System, 1995: MMWR Morb Mortal Wkly Rep 1 997, 46:1018-1023.
38. 38 Bowyer NK: A primary care team approach to the prevention of ocular complications of diabetes: a program review. J Am Optom Assoc 1997, 68:232-242.
39. 39 Kelly W, Bilous R, Murray G: A comprehensive register for diabetic outpatients: experience with desktop computing from 1987-1996. Comput Methods Programs Biomed 1998, 56:205-210.
40. 40 Morris AD, Boyle DI, MacAlpine R, et al.: The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997, 315:524-528.
41. 41 Marcus DM, Brooks SE, Ulrich LD, et al.: Telemedicine diagnosis of eye disorders by direct ophthalmoscopy. A pilot study. Ophthalmology 1998, 105: 1907-1914.
42. 42 Zahlmann G, Walther HD, Liesenfeld B, et al.: Teleconsultation network for ophthalmology-experiences and results. Klin Monatsbl Augenheilkd 1998, 212:111-115.
43. 43 Hernaez Ortega MC, Soto Pedre E, Vazquez JA, et al.: Study of the efficiency of a non-mydriatic retinal camera in the diagnosis of diabetic retinopathy. Rev Clin Esp 1998, 198:194-199.
44. 44 Penman AD, Saaddine JB, Hegazy M, et al.: Screening for diabetic retinopathy: the utility of nonmydriatic retinal photography in Egyptian adults. Diabet Med 1998, 15:783-787.
45. 45 Aiello LM, Bursell SE, Cavallerano J, et al.: Joslin Vision Network Validation Study: pilot image stabilization phase. J Am Optom Assoc 1998, 69:699-710.
46. 46 Harper CA, Livingston PM, Wood C, et al.: Screening for diabetic retinopathy using a non-mydriatic retinal camera in rural Victoria. Aust N Z J Ophthalmol 1998, 26:117-121.
47. 47 Kuiv R, Tein P, Algvere PV, et al.: Photographic detection of retinopathy in insulin-treated diabetes. A population study in the city of Tartu, Estonia, Acta Ophthalmol Scand 1997, 75:447-456.
48. 48 Ryder RE, Kong N, Bates AS: Instant electronic imaging systems are superior to Polaroid at detecting sight-threatening diabetic retinopathy. Diabet Med 1998, 15:254-258.
49. 49 Backlund LB, Algvere PV, Rosenqvist U: Early detection of diabetic retinopathy by a mobile retinal photography service working in partnership with primary health care teams. Diabet Med 1998, 15(suppl 3):S32-S37.
50. 50 George LD, Halliwell M, Hill R, et al.: A comparison of digital retinal images and 35mm color transparencies in detecting and grading diabetic retinopathy. Diabet Med 1998, 15:250-253.
51. 51 Cree MJ, Olson JA, McHardy KC, et al.: A fully automated comparative microaneurysm digital detection system. Eye 1997, 11:622-628.
52. 52 Dosso AA, Yenice Ustun F, Sommerhalder J, et al.: Contrast sensitivity in obese dyslipidemic patients with insulin resistance. Arch Ophthalmol 1998, 116:1316-1320.
53. 53 Palmowski AM, Sutter EE, Bearse MA Jr, Fung W: Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci 1997, 38:2586-2596.
54. 54 Tregear SJ, Knowles PJ, Ripley LG, Casswell AG: Chromatic-contrast threshold impairment in diabetes. Eye 1997, 11:537-546.
55. 55 Hee MR, Puliafito CA, Duker JS, et al.: Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998, 105:360-370.
56. 56 Delorme C, Boisjoly HM, Baillargeon L, et al.: Screening for diabetic retinopathy. Do family physicians know the Canadian guidelines? Can Fam Physician 1998, 44:1473-1479.
57. 57 Pointer JS, Baranyovits P, O'Malley BP: The Kettering Diabetic Monitoring Program: twelve months experience of an optometric practice-based scheme. Ophthalmic Physiol Opt 1998, 18:401-407.
58. 58 Leese GP, Tesfaye S, Dengler Harles M, et al.: Screening for diabetic eye disease by optometrists using slit lamps. J R Coll Physicians Lond 1997, 31:65-69.
59. 59 Burnett S, Hurwitz B, Davoy C, et al.: The implementation of prompted retinal screening for diabetic eye disease by accredited optometrists in an inner-city district of North London: a quality of care study. Diabet Med 1998, 15(suppl 3):S38-S43.
60. 60 Jude EB, Ryan B, O'Leary BM, et al.: Pupillary dilatation and driving in diabetic patients. Diabet Med 1998, 15:143-147. Pupillary dilatation and its effect on visual acuity has implications for routine screening.
61. 61 Browning DJ, Zhang Z, Benfield JM, Scott AQ: The effect of patient characteristics on response to focal laser treatment for diabetic macular edema. Ophthalmology 1997, 104:466-472.
62. 62 Pearson AR, Tanner V, Keightley SJ, Casswell AG: What effect does laser photocoagulation have on driving visual fields in diabetics? Eye 1998, 12: 64-68.
63. 63 Mackie SW, Walsh G: Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt 1998, 18: 173-181.
64. 64 Oberg ED, Barrett SF, Wright CH: Development of an integrated automated retinal surgical laser system. Biomed Sci Instrum 1997, 33:77-81.
65. 65 Oberg ED, Barrett SF, Wright CH: The development of a hybrid analog/digital retinal surgical laser system. Biomed Sci Instrum 1997, 34:224-228.
66. 66 The Diabetic Retinopathy Vitrectomy Study: Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial (Diabetic Retinopathy Vitrectomy Study rep, no. 5). Arch Ophthalmol 1990, 108:958-964.
67. 67 Hikichi T, Fujio N, Akiba J, et al.: Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 1997, 104:473-478.
68. 68 Sosna T, Saudek F, Dominek Z: Effect of successful combined renal and pancreatic transplantation on diabetic retinopathy. Acta Univ Palacki Olomuc Fac Med 1998, 141:75-77.
69. 69 Montenegro MH: Retinal blood flow in diabetes. Int Ophthalmol Clin 1998, 38:103-110.
70. 70 Cogan D, Toussaint D, Kuwabara T: Retinal vascular pattern: IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
71. 71 Bollineni JS, Alluru I, Reddi AS: Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 1997, 16:127-130.
72. 72 Larkins RG, Dunlop ME, Johnson EIM: The pathogenesis of diabetic retinopathy. Aust N Z J Ophthalmol 1996, 24:97-103.
73. 73 Patel V, Rassam SMB, Chen HC, et al.: Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Metabolism 1998, 478(suppl 1):28-33.
74. 74 Tolentino MJ, Adamis AP: Angiogenic factors in the development of diabetic iris neovascularization and retinopathy. Int Ophthalmol Clin 1998, 38:77-94.
75. 75 Montenegro MH: Retinal blood flow in diabetes. Int Ophthalmol Clin 1998, 38:103-110.
76. 76 Kinoshita J: Aldose reductase in the diabetic eye: XLIII. Edward Jackson Memorial Lecture. Am J Ophthalmol 1986, 102:685-692.
77. 77 Shiba T, Inoguchi T, Sportsman JR, et al.: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993, 265:E783-E793.
78. 78 Sugaya K, Fukagawa T, Matsumotot KT, et al.: Three genes in the human MHC class III region near the junction with class II: gene for receptor of advanced glycosylation end productions, BPX2 homeobox gene and Notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994, 23:408-419.
79. 79 Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci 1998, 39:2517-2523.
80. 80 Hashimoto H, et al.: Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous. Nippon Ganka Gakkai Zasshi 1998, 102:442-446.
81. 81 Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y: Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998, 41:131-137.
82. 82 Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1308.
83. 83 Keck PJ, Hauser SD, Krivi G, et al.: Vascular permeability factor, and endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1311.
84. 84 Mathews MK, Merges C, McLeod DS, et al.: Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38:2729-2741.
85. 85 Amin RH, Frank RN, Kennedy A, et al.: Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997, 38: 36-47.
86. 86 Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997, 13:37-50.
87. 87 Khaliz A, Foreman D, Ahmed A, et al.: Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 1998, 78:109-116.
88. 88 Tolentino MJ, Miller JW, Gragoudas ES, et al.: Intravitreous injections of VEGF produce retinal ischaemia and microangiopathy in an adult primate. Ophthalmol 1996, 103:1820-1828.
89. 89 Wu HM, et al.: Role of phospholipase C, protein kinase C and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 1999, 276:H535-H542.
90. 90 Danis RP, et al.: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998, 39:171-179.
91. 91 Park JY, et al.: The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit Dial Int 1999, 19(suppl 2):S222-S227.
92. 92 Aiello LP, et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
93. 93 Gilbert RE, Vranes D, Berka JL, et al.: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998, 78:1017-1027.
94. 94 Higashi S, Clermont AC, Dhir V, Bursell SE: Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes 1998, 47:653-659.
95. 95 Clermont AC, Aiello LP, Mori F, et al.: Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression on nonproliferative diabetic retinopathy. Am J Ophthalmol 1997, 124:433-446.
96. 96 Otani A, et al.: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998, 82:619-618.
97. 97 Robison WG Jr, Laver NM, Jacot JL, et al.: Efficacy of treatment after measurable diabetic like retinopathy in galactose-fed rats. Invest Ophthalmol Vis Sci 1997, 38:1066-1073.
98. 98 The EUCLID study group: randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 341:1306-1309.
99. 99 Charturvedi N, Sjolie A-K, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. Lancet 1998, 351:28-31.
100. 100 Stoschitzky K: Angiotensinll, VEGF and diabetic retinopathy. Lancet 1998, 351:836-837.
101. 101 Donnelly R, et al.: Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Clin Exp Pharmacol Physiol 1998, 25:79-87.
102. 102 Hiller R, Sperduto RD, Podgor MJ, et al.: Cigarette smoking and the risk of development of lens opacities. The Framingham studies. Arch Ophthalmol 1997, 115:1113-1118.
103. 103 Klein BE, Klein R, Lee KE: Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities. The Beaver Dam Eye Study. Am J Ophthalmol 1998, 126:782-790.
104. 104 Klein BE, Klein R, Lee KE: Renal function abnormalities and incident cataract after a 5-year interval: the Beaver Dam Eye Study. Curr Eye Res 1998, 17: 720-725.
105. 105 Chiu DW, Meusemann RA, Kaufman DV, et al.: Visual outcome and progression of retinopathy after cataract surgery in diabetic patients. Aust N Z J Ophthalmol 1998, 26:129-133.
106. 106 Dowler JGF, Sehmi KS, Hykin PG, Hamilton AMP: The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999, 106: 663-668. This paper has implications for cataract in diabetic maculopathy and the timing of postoperative treatment.
107. 107 Tsujikawa A, Otani A, Akanashi T, Ogura Y: Long-term prognosis of extracapsular cataract extraction and intraocular lens implantation in diabetic patients. Jpn J Ophthalmol 1997, 41:319-323.
108. 108 Laurell CG, Zetterstrom C, Philipson B, et al.: Randomized study of the blood-aqueous barrier reaction after phacoemulsification and extracapsular cataract extraction. Acta Ophthalmol Scand 1998, 76:573-578.
109. 109 Zaczek A, Zetterstrom C: Aqueous flare intensity after phacoemulsification in patients with diabetes mellitus. J Cataract Refract Surg 1998, 24:1099-1104.
110. 110 Hayashi H, Hayashi K, Nakao F, Hayashi F: Area reduction in the anterior capsular opening in eyes of diabetes mellitus patients. J Cataract Ref Surg 1998, 24:1105-1110.
111. 111 Zaczek A, Zetterstrom C: Posterior capsule opacification after phacoemulsification in patients with diabetes mellitus. J Cataract Refract Surg 1998, 25: 233-237.
112. 112 Ionides A, Dowler JGF, Hykin PG, et al.: Posterior capsule opacification following diabetic extracapsular cataract extraction. Eye 1994, 8:535-537.
113. 113 Mester U, Strauss M, Grewing R: Biocompatibility and blood-aqueous barrier impairment in at-risk eyes with heparin-surface-modified or unmodified lenses. J Cataract Refract Surg 1998, 24:380-384.
114. 114 Tabbara KF, Al Kaff AS, Al Rajhi AA, et al.: Heparin surface-modified intraocular lenses in patients with inactive uveitis or diabetes. Ophthalmology 1998, 105:843-845.
115. 115 Hinkelmann L, Struck HG, Lautenschlager C: Inflammatory reaction of the anterior eye segment. Cataract extraction in patients with and without diabetes mellitus. Ophthalmologe 1998, 95:213-218.
116. 116 Kruger AJ, Schauersberger J, Petternel V, Amon M: Inflammation after phacoemulsification in patients with type 2 diabetes mellitus without retinopathy: prospective study. J Cataract Refract Surg 1999, 25:227-232.
117. 117 Tan DT, Chee SP, Lim L, Lim AS: Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 1999, 106:223-231.